A new prize system for drug innovation

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Innovation Management

Background:

• Current pharmaceutical patent systems may not fully align innovator rewards with societal health benefits.
• Information asymmetry regarding drug value and potential overuse complicates reward determination.

Purpose of the Study:

• To propose a new prize (reward) system for drug innovation.
• To establish a system that bases rewards on the quantified value of health benefits over time.
• To create optimal incentives for research and development (R&D) investment.

Main Methods:

• Developing a reward system where payment is contingent on accrued health benefits.
• Determining the willingness to pay for a unit of health benefit using cost-effectiveness ratios from palliative/nursing care.
• Mathematically linking reward size to information uncertainty, including potential drug overuse, to address information gaps.

Main Results:

• The proposed system rewards drug innovators based on the social value of their innovations.
• It provides optimal incentives for R&D by aligning rewards with societal impact.
• The system aims to mitigate excessive marketing by both innovators and generic drug producers.

Conclusions:

• The proposed prize system offers a viable, non-voluntary alternative to the current patent system.
• It ensures that rewards accurately reflect the true health benefits and social value of drug innovations.
• This model promotes more efficient and socially beneficial drug development.